ARCHIVES

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

This article is from The Cancer Letter archive.

Vol. 38 No. 18 | May 4, 2012

Download PDF Visit The Full Archive

Related Articles

Long-term Hormonal Therapy Adds No Additional Benefits

September 27, 2013

In Brief: Cancer Panel To Meet In Seattle, Houston, Chicago; Wisconsin’s Robert Johnson Dies; Goldin Retires

August 27, 1982

NCI funds biorepository for prostate cancer SPOREs.

November 11, 2005

Carbone to Give Up ECOG Chairmanship; DCE’s Adamson Receives Presidential Executive Award

October 6, 1989

NCI Plans Preclinical Studies Of Endoxifen, A Tamoxifen Metabolite.

August 7, 2009

Cooperative Group Chairman Objects “Personal” Comments, Other Deficiencies In Peer Review

January 16, 1981